193 related articles for article (PubMed ID: 21964579)
1. Improving communication of breast cancer recurrence risk.
Brewer NT; Richman AR; DeFrank JT; Reyna VF; Carey LA
Breast Cancer Res Treat; 2012 Jun; 133(2):553-61. PubMed ID: 21964579
[TBL] [Abstract][Full Text] [Related]
2. Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy.
Lillie SE; Brewer NT; O'Neill SC; Morrill EF; Dees EC; Carey LA; Rimer BK
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):249-55. PubMed ID: 17267389
[TBL] [Abstract][Full Text] [Related]
3. Women's experiences with genomic testing for breast cancer recurrence risk.
Tzeng JP; Mayer D; Richman AR; Lipkus I; Han PK; Valle CG; Carey LA; Brewer NT
Cancer; 2010 Apr; 116(8):1992-2000. PubMed ID: 20213682
[TBL] [Abstract][Full Text] [Related]
4. Understanding how breast cancer patients use risk information from genomic tests.
DeFrank JT; Carey LA; Brewer NT
J Behav Med; 2013 Dec; 36(6):567-73. PubMed ID: 22878783
[TBL] [Abstract][Full Text] [Related]
5. The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence.
Janz NK; Li Y; Zikmund-Fisher BJ; Jagsi R; Kurian AW; An LC; McLeod MC; Lee KL; Katz SJ; Hawley ST
Breast Cancer Res Treat; 2017 Feb; 161(3):525-535. PubMed ID: 27943007
[TBL] [Abstract][Full Text] [Related]
6. Health literacy and cancer risk perception: implications for genomic risk communication.
Brewer NT; Tzeng JP; Lillie SE; Edwards AS; Peppercorn JM; Rimer BK
Med Decis Making; 2009; 29(2):157-66. PubMed ID: 19050227
[TBL] [Abstract][Full Text] [Related]
7. Knowledge about genomic recurrence risk testing among breast cancer survivors.
Lipkus IM; Vadaparampil ST; Jacobsen PB; Miree CA
J Cancer Educ; 2011 Dec; 26(4):664-9. PubMed ID: 21688183
[TBL] [Abstract][Full Text] [Related]
8. Who gets genomic testing for breast cancer recurrence risk?
DeFrank JT; Salz T; Reeder-Hayes K; Brewer NT
Public Health Genomics; 2013; 16(5):215-22. PubMed ID: 23899493
[TBL] [Abstract][Full Text] [Related]
9. When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.
Brewer NT; Edwards AS; O'Neill SC; Tzeng JP; Carey LA; Rimer BK
Breast Cancer Res Treat; 2009 Sep; 117(1):25-9. PubMed ID: 18785002
[TBL] [Abstract][Full Text] [Related]
10. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
11. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
12. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
14. Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
Evans CN; Brewer NT; Vadaparampil ST; Boisvert M; Ottaviano Y; Lee MC; Isaacs C; Schwartz MD; O'Neill SC
Breast Cancer Res Treat; 2016 Apr; 156(3):549-555. PubMed ID: 27059031
[TBL] [Abstract][Full Text] [Related]
15. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
Gage MM; Mylander WC; Rosman M; Fujii T; Le Du F; Raghavendra A; Sinha AK; Espinosa Fernandez JR; James A; Ueno NT; Tafra L; Jackson RS
Ann Oncol; 2018 May; 29(5):1280-1285. PubMed ID: 29788166
[TBL] [Abstract][Full Text] [Related]
16. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
17. Explicit prognostic disclosure to Asian women with breast cancer: A randomized, scripted video-vignette study (J-SUPPORT1601).
Mori M; Fujimori M; van Vliet LM; Yamaguchi T; Shimizu C; Kinoshita T; Morishita-Kawahara M; Inoue A; Inoguchi H; Matsuoka Y; Bruera E; Morita T; Uchitomi Y
Cancer; 2019 Oct; 125(19):3320-3329. PubMed ID: 31206639
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
[TBL] [Abstract][Full Text] [Related]
20. Women's interest in gene expression analysis for breast cancer recurrence risk.
O'Neill SC; Brewer NT; Lillie SE; Morrill EF; Dees EC; Carey LA; Rimer BK
J Clin Oncol; 2007 Oct; 25(29):4628-34. PubMed ID: 17925559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
